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Don’t Forget the Brain: Lifestyle
Medicine in the Century of
Neurodegeneration
Abstract: Neurology is often not
discussed in lifestyle medicine circles,
but it might be an area that will
propel the cause of lifestyle medicine
in the future. This is especially
relevant in increasingly common
neurodegenerative conditions such
as Alzheimer’s disease, which have
no known disease modifying therapy
but lifestyle factors are implicated in
causation.
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I can think of no other disease that
has such a profound effect on loss of
function, loss of independence, and
the need for care. I can think of no
other disease so deeply dreaded by
anyone who wants to age gracefully
and with dignity. I can think of no
other disease that places such a
heavy burden on families,
communities, and societies. I can
think of no other disease where
innovation, including breakthrough
discoveries to develop a cure, is so
badly needed.

—Dr Margaret Chan, Director-General of
the World Health Organization, at the
Conference on Global Action Against
Dementia, March 20151

In an article titled “A Tale of Coronary
Artery Disease and Myocardial
Infarction,” published in the celebratory
200th year edition of the New England

article was the evidence-base for lifestyle
interventions in the primary, secondary,
and tertiary prevention of cardiovascular
conditions. Indeed, one of the greatest
impediments to the widespread
acceptance and embrace of lifestyle
medicine for the prevention and
treatment of cardiovascular disease is the
availability of other options.

When it comes to
neurodegenerative conditions such
as dementia, . . . treatment options
are lacking. Encouragingly, the
evidence-base for lifestyle as
therapy is emerging.
Journal of Medicine, the authors shared a
success story.2 They presented data
showing a decline in cardiovascular
mortality and hinted toward an optimistic
outlook, predicated on innovations in
surgical and pharmacological
interventions. Glaringly absent in the

However, when it comes to
neurodegenerative conditions such as
dementia, the prevalence and burden of
which is rising sharply, treatment
options are lacking. Encouragingly, the
evidence-base for lifestyle as therapy is
emerging.
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Alzheimer’s is the only disease in the
top 10 causes of death in the United
States to rise in the past decade.3 In
2014, the prevalence of diagnosed
Alzheimer’s rose by 10%, making it now
the sixth leading cause of death.4 In
Australia, if present trends continue,
dementia will overtake coronary heart
disease as the leading cause of death
within 5 years.5 Indeed, the 21st century
is being referred to as “the century of
neurodegeneration.”6 As the statistics
escalate, the medical profession, from
primary care physicians and geriatricians
to researchers,7 and even the World
Health Organization (see opening quote)
are frustrated by the lack of any effective
therapies.
The rise of neurological diseases,
specifically dementia, may present
lifestyle medicine with a unique
opportunity to receive the prominence it
deserves. Dementia is “a relentlessly
progressive terminal illness”6 for which
there are no surgical or pharmacological
treatment options. However, there is
good evidence that a healthy lifestyle is
protective against the condition.
As much as one third of Alzheimer’s
disease is attributable to modifiable risk
factors, most of which have lifestyle
underpinnings: physical inactivity,
smoking, hypertension, obesity,
diabetes, and depression.8 Furthermore,
the pathogenesis of Alzheimer’s disease
implicates lifestyle-induced vascular
lesions and poor perfusion, to the
extent that Alzheimer’s is now
considered a combination of
cardiovascular disease and
neurodegeneration.9 Alzheimer’s has
also been referred to as “type 3
diabetes”10 because of the similarities in
the risk factors, metabolic disorder, and
pathology of the two conditions.11 As
with other chronic conditions,
inflammation and oxidative stress have
been identified as underpinning the
progression of neurodegeneration.12
These findings highlight the lifestyle
connection to neurodegenerative
conditions, and it is becoming
increasingly clear that a healthy lifestyle
can prevent Alzhiemer’s.13

Furthermore, there is emerging
evidence that healthy lifestyle practices
may be effective in the management and
even treatment of dementia and its
associated symptoms. In an article titled
“Why Has Therapy Development for
Dementia Failed in the Last Two
Decades?”7 Gauthier and associates
conclude that the only “encouraging new
data” was from the Finnish Geriatric trial
where cognitive decline in at-risk
individuals was reduced by diet, exercise,
cognitive training, and vascular risk
monitoring.14 This large study has lent
support to the results of a small study of
10 subjects with dementia where a
complex intervention incorporating a
healthy diet, sleep hygiene, physical
activity, stress management, and
nutritional supplements resulted in all but
one subject experiencing sustained
improvement in cognition and reversal of
memory loss.15
Are we are at the stage today with
neurodegenerative conditions that we
were at 35 years ago with cardiovascular
disease, when Ornish and colleagues16
showed the viability of intensive
therapeutic lifestyle change?
For many years we have received
unsolicited reports from participants
in the Complete Health Improvement
Program (CHIP)17 of a “fog lifting
from my brain.” Presently we are
investigating this phenomenon
further by exploring changes in
cognitive function and decline in
response to CHIP (ANZCTR
ACTRN12616000720415),18 but what
has been intriguing in conducting the
trial is the receptiveness of both
participants and medical practitioners.
Faced with cognitive decline and a
daunting prognosis, participants
demonstrated a high readiness for
change, while medical practitioners,
recognizing the dearth of treatment
options, have been refreshingly
receptive to lifestyle medicine.
Neurology is often not discussed in
lifestyle medicine circles, but it might be
an area that will propel the cause of
lifestyle medicine in the future. So as we
champion lifestyle medicine moving
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forward, let us not forget about
the brain. AJLM
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